Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of the National Cancer Institute

• Publication date

  2013-06-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jnci/djt095PMID 23628597
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers

  2012cited by this paper
• Contrasting treatment‐specific survival using double‐robust estimators

  2012cited by this paper
• Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

  2011cited by this paper
• Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.

  2010cited by this paper
• Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer

  2010cited by this paper
• Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.

  2010cited by this paper
• High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series

  2010cited by this paper
• Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.

  2010cited by this paper
• Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis

  2010cited by this paper
• Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study

  2010cited by this paper
• Genetic susceptibility to breast cancer

  2010cited by this paper
• Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.

  2010cited by this paper
• Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

  2010cited by this paper
• A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population

  2010cited by this paper
• Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age

  2010cited by this paper
• Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.

  2009cited by this paper
• Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers

  2009cited by this paper
• Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers

  2009cited by this paper
• Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features.

  2009cited by this paper
• Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence

  2009cited by this paper
• Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.

  2009cited by this paper
• Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family

  2008cited by this paper
• The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions

  2008cited by this paper
• Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.

  2008cited by this paper
• Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.

  2008cited by this paper
• Variation of breast cancer risk among BRCA1/2 carriers.

  2008cited by this paper
• Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.

  2007cited by this paper
• A prospective study of breast cancer risk in relatives of BRCA1/BRCA2 mutation carriers.

  2007cited by this paper
• RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.

  2007cited by this paper
• Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.

  2007cited by this paper
• Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.

  2007cited by this paper
• Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations

  2007cited by this paper
• An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)

  2007cited by this paper
• Prophylactic oophorectomy in women at increased cancer risk

  2007cited by this paper
• Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.

  2007cited by this paper
• Characterization of BRCA1 and BRCA2 mutations in a large United States sample.

  2006cited by this paper
• Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.

  2006cited by this paper
• Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS).

  2006cited by this paper
• Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers.

  2006cited by this paper
• Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.

  2006cited by this paper
• Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

  2005cited by this paper
• Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers

  2005cited by this paper
• Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.

  2005cited by this paper
• Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

  2004cited by this paper
• Breast Cancer Risks for BRCA1/2 Carriers

  2004cited by this paper
• Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

  2003cited by this paper
• Variation in BRCA1 cancer risks by mutation position.

  2002cited by this paper
• On the use of familial aggregation in population-based case probands for calculating penetrance.

  2002cited by this paper
• Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.

  2002cited by this paper
• Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

  2002cited by this paper
• Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

  2002cited by this paper
• Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

  2002cited by this paper
• Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.

  2002cited by this paper
• The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

  2001cited by this paper
• Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

  2001cited by this paper
• Variation in cancer risks, by mutation position, in BRCA2 mutation carriers.

  2001cited by this paper
• Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

  2001cited by this paper
• Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

  2001cited by this paper
• Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases

  2000cited by this paper
• Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.

  2000cited by this paper
• Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.

  2000cited by this paper
• The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.

  1999cited by this paper
• Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.

  1999cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.

  1999cited by this paper
• Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.

  1999cited by this paper
• Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

  1998cited by this paper
• Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene

  1997cited by this paper
• Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13.

  1997cited by this paper
• The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

  1997cited by this paper
• Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

  1995cited by this paper
• Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence.

  1995cited by this paper
• Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

  1994cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Harnessing genomics for early cancer detection, risk stratification and prevention.

  2026cites this paper
• Screening for Hereditary Cancer Syndromes

  2026cites this paper
• Nachsorge Ovarialkarzinom: zwischen Erhaltungstherapie und Rezidiv

  2026cites this paper
• Survival Outcomes With or Without Risk-Reducing Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers.

  2026cites this paper
• Bidirectional effect of intestinal microbiome and host in circadian rhythm disruption: Environmental factors and breast cancer development.

  2026cites this paper
• Integrating genomic and non-genomic data to stratify the risk of contralateral breast cancer after radiotherapy.

  2026cites this paper
• Genetic Basis of Familial Cancer Risk: A Narrative Review

  2026cites this paper
• Beyond BRCA: A scoping review of person-centred care for women diagnosed with a BRCA gene mutation

  2025cites this paper
• Impact on Global Health Status, Quality-Sexual Life and Chronic Fatigue State of Risk-Reducing Salpingo-Oophorectomy in Women Who Are BRCA1/2 Mutation Carriers: Experience from a Third-Level Italian Center

  2025cites this paper
• Breast Cancer Occurrence After Risk-reducing Mastectomies in 274 Cases: A Single Center With More Than 42 Years of Experience

  2025cites this paper
• Natural products as part of triple negative breast cancer

  2025cites this paper
• Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial–Mesenchymal Transition

  2025cites this paper
• Diagnostic sensitivity of mammography and magnetic resonance imaging for ductal carcinoma in situ in high-risk breast cancer screening: A systematic-review and meta-analysis.

  2025cites this paper
• Protocol of the SOCFC project: a longitudinal cohort study of ovarian cancer patients, high-risk populations, and healthy controls to identify factors and biomarkers associated with disease diagnosis and prognosis

  2025cites this paper
• Cost-Effectiveness Analysis of Tumor Testing for BRCA Pathogenic Variants in Epithelial Ovarian Cancer.

  2025cites this paper
• Long-Term Oncologic Outcome of Breast-Conserving Treatment in Patients With Breast Cancer With BRCA Variants

  2025cites this paper
• De novo familial adenomatous polyposis with germline double heterozygosity of APC/BRCA2: a case report and literature review

  2025influential citation
• Time trends, uptake, and oncological effects of risk-reducing surgeries in 3067 Danish BRCA1/2 carriers: a population-based study with matched controls

  2025cites this paper
• Predicting the likelihood of carrying BRCA1 or BRCA2 pathogenic variants in high-risk Pakistani breast cancer patients

  2025cites this paper
• Single-Cell Immune Signature and Response to Neoadjuvant Chemotherapy in BRCA1/2-Mutated Breast Cancer.

  2025cites this paper
• Screening, Risk Reduction Strategies, and Clinical Management of Unaffected Carriers of BRCA1 or BRCA2 Pathogenic Variants

  2025influential citation
• Association of Polygenic-Based Breast Cancer Risk Prediction With Patient Management

  2025cites this paper
• The difference in contralateral breast cancer and ovarian cancer risks for BRCA1 founder variant (c.5266dup, c.4035del) carriers with primary breast cancer

  2025cites this paper
• The homologous recombination factors BRCA2 and PALB2 interplay with mismatch repair pathways to maintain centromere stability and cell viability

  2025cites this paper
• The long road to unbiased estimates of pancreatic cancer incidence in the hereditary breast and ovarian cancer syndrome

  2025cites this paper
• Gastric epithelium from BRCA1 and BRCA2 carriers harbors increased double-stranded DNA damage and augmented growth

  2025cites this paper
• Synchronous Breast and Kidney Carcinomas Following Treatment for Hodgkin’s Lymphoma in Young Adulthood: A Case Report and Literature Review

  2025cites this paper
• Radiation-guided nanoparticles enhance the efficacy of PARP inhibitors in primary and metastatic BRCA1-deficient tumors via Immunotherapy.

  2025cites this paper
• Nano-based Drug Delivery System for Treating Triple-negative Breast Cancer (TNBC)

  2025influential citation
• Patterns of Homologous Repair Deficiency and BRCA1 / 2 Testing of Ovarian and Breast Cancers: A Real-World Study of Patients in Community Health Settings in the United States

  2025cites this paper
• Estimating Cancer Penetrance in Carriers of BRCA2 Pathogenic Variants Using Cancer‐Specific Polygenic Scores

  2025cites this paper
• The Relationship Between BRCA1 Expression and Grade in Breast Cancer Patients in NTB

  2025cites this paper
• Contralateral breast cancer in patients carrying mutations in the BRCA1/2 gene

  2025cites this paper
• The influence of breast cancer susceptibility genes on radiotherapy efficacy and adverse toxicities

  2025cites this paper
• RANKL and CSF-1 are elevated in periovulatory follicular fluid of BRCA1 mutation carriers and increase proinflammatory signaling in fallopian tube epithelial cells

  2025cites this paper
• Correcting Decades of Misinformation About Breast Cancer Screening: An Open Letter to Women and Those Who Advise Them About Screening for Breast Cancer.

  2025cites this paper
• The e-BRAVE study: A prospective web-based cohort and biobank of women carriers of BRCA mutations

  2025cites this paper
• Carcinogenic form and characteristics of BRCA pathogenic variant breast cancer

  2025cites this paper
• Breast cancer incidence and subtype patterns among BRCA-mutated ovarian cancer patients: a systematic review and meta-analysis

  2025cites this paper
• The Role of Mediterranean Diet and Intermittent Fasting in Modulating Inflammation and Clinical Biochemistry Markers in Hereditary Cancer Syndromes: A Review

  2025cites this paper
• Poly(ADP-ribose) polymerase-1 in breast cancers: expression level and its association in various molecular subtypes with a focus in Africa

  2025cites this paper
• Recent findings on the PD-1/PD-L1 Axis in breast cancer: Molecular mechanisms, immunotherapeutic potentials, and clinical implications.

  2025cites this paper
• Germline Variants in the Immune Response-Related Genes: Possible Modifying Effect on Age-Dependent BRCA1 Penetrance in Breast Cancer Patient

  2025cites this paper
• Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records.

  2025cites this paper
• Understanding Susceptibility to Breast Cancer: From Risk Factors to Prevention Strategies

  2025cites this paper
• A novel Harris Hawks Optimization-based clustering method for elucidating genetic associations in osteoarthritis and Diverse Cancer Types

  2025cites this paper
• Distribution of HER2 Low in Tumors of Patients With Hereditary Breast Cancer According to Germline Pathogenic or Likely Pathogenic Genetic Variants.

  2025cites this paper
• Pathology results of risk‐reducing salpingo‐oophorectomy in BRCA1/2 carriers and long‐term clinical outcomes

  2025cites this paper
• Retrospective Study of Genetic Testing Results Reveals Pathogenic Variants Beyond BRCA1/2 in Hereditary Breast and Ovarian Cancer Cases in New Brunswick: Implications for Future Care

  2025cites this paper
• Incidental finding of a BRCA2 variant following whole genome sequencing to molecularly diagnose bilateral congenital cataracts

  2024cites this paper
• Advancements in targeting tumor suppressor genes (p53 and BRCA 1/2) in breast cancer therapy

  2024cites this paper
• Uptake of Risk‐Reducing Salpingo‐Oophorectomy and Gynaecologic Surveillance Among Germline BRCA Pathogenic Variants Carriers

  2024cites this paper
• Multiple primary tumors in a patient with non‑small‑cell lung cancer harboring mutations in ERCC6 and LYL1: A case report

  2024cites this paper
• Clinically Significant BRCA1 and BRCA2 Germline Variants in Breast Cancer—A Single-Center Experience

  2024cites this paper
• The Association Between Breast Cancer Predisposing Genetic Variants and Multifocal, Multicentric Breast Cancer

  2024cites this paper
• Establishment of a clinical cancer genetics program for breast cancer in a resource-limited country; challenges and opportunities

  2024cites this paper
• High-grade serous ovarian cancer after bilateral salpingo-oophorectomy.

  2024cites this paper
• Reduced penetrance BRCA1 and BRCA2 pathogenic variants in clinical germline genetic testing

  2024cites this paper
• Clinical Impact of Constitutional Genomic Testing on Current Breast Cancer Care.

  2024cites this paper
• Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review.

  2024cites this paper
• Precision therapy for cancer prevention by targeting carcinogenesis

  2024cites this paper
• Risk-reducing surgeries for breast cancer in Brazilian patients undergoing multigene germline panel: impact of results on decision making

  2024cites this paper
• Multiomics analysis of homologous recombination deficiency across cancer types

  2024cites this paper
• Impact of family dynamics on cancer progression and patient outcomes: An analysis of emotional and psychological support

  2024cites this paper
• Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene.

  2024cites this paper
• Advancing personalized medicine: Integrating statistical algorithms with omics and nano-omics for enhanced diagnostic accuracy and treatment efficacy.

  2024cites this paper
• Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study.

  2024cites this paper
• Identification of key molecular pathways and genes in BRCA1 and BRCA2-mutant ovarian cancer: evidence from bioinformatics analysis

  2024cites this paper
• HLA gene polymorphism is a modifier of age-related breast cancer penetrance in carriers of BRCA1 pathogenic alleles

  2024cites this paper
• A pilot randomized controlled study to determine the effectiveness of video educational tool in BRCA1/2 pre‐test counseling for Japanese breast cancer patients

  2024cites this paper
• ANÁLISE QUANTITATIVA DE INTERNAÇÕES POR NEOPLASIA MALIGNA DE MAMA NO BRASIL

  2024cites this paper
• Mutation characteristics of cancer susceptibility genes in Chinese ovarian cancer patients

  2024cites this paper
• Decision aids for female BRCA mutation carriers: a scoping review

  2024cites this paper
• Predictive Value and Therapeutic Significance of Somatic BRCA Mutation in Solid Tumors

  2024cites this paper
• Research Progress of Neoadjuvant Chemotherapy for Advanced Ovarian Cancer

  2024cites this paper
• Characterization of immortalized ovarian epithelial cells with BRCA1/2 mutation

  2024cites this paper
• Management and Clinical Outcomes of Breast Cancer in Women Diagnosed with Hereditary Cancer Syndromes in a Clinic-Based Sample from Colombia

  2024cites this paper
• Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: lower rates for 5-years post chemotherapy.

  2024cites this paper
• Characteristics of germline DNA damage response gene mutations in ovarian cancer in Southwest China

  2024cites this paper
• Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing

  2024influential citation
• Increased risk of contralateral breast cancer for BRCA1/2 wild-type, high-risk Korean breast cancer patients: a retrospective cohort study

  2024cites this paper
• Untapped Potential of Poly(ADP-Ribose) Polymerase Inhibitors: Lessons Learned From the Real-World Clinical Homologous Recombination Repair Mutation Testing

  2024cites this paper
• Characterization of a germline variant TNS1 c.2999-1G > C in a hereditary cancer syndrome family.

  2024cites this paper
• Baseline DSB repair prediction of chronic rare Grade ≥ 3 toxicities induced by radiotherapy using classification algorithms

  2024cites this paper
• ER-positive and BRCA2-mutated breast cancer: a literature review

  2024influential citation
• Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline

  2024cites this paper
• Implications of Highly Penetrant Genetic Variants on Breast Surgery.

  2024cites this paper
• TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations

  2024influential citation
• Association Between Germline BRCA1/2 Gene Variants and Clinicopathological Features of Ovarian Cancer

  2024cites this paper
• Prevalence, prognosis, and health care resource utilization in carriers of pathogenic germline variants in BRCA1/2 with incident early-stage breast cancer: a Finnish population-based study

  2024cites this paper
• Aqueous Extracts of Ocimum gratissimum Sensitize Hepatocellular Carcinoma Cells to Cisplatin through BRCA1 Inhibition

  2024influential citation
• BRCA1/2 Mutations and Breast/Ovarian Cancer Risk: A New Insights Review

  2024cites this paper
• Epidemiology and risk factors for ovarian cancer

  2023influential citation
• Global trends in BRCA-related breast cancer research from 2013 to 2022: A scientometric analysis

  2023cites this paper
• Investigation of BRCA2 Gene K3326X Variant in Patients with Breast and Ovarian Cancer by Next-Generation Sequencing Technique

  2023cites this paper
• Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials

  2023cites this paper
• PARG inhibition induces nuclear aggregation of PARylated PARP1

  2023cites this paper
• Targeted Gene Panel Sequencing Unveiled New Pathogenic Mutations in Patients With Breast Cancer

  2023cites this paper
• A Genetic Revolution: Cancer Genetic Testing and Counseling.

  2023cites this paper
• Pivotal Role of Genetic Counselors in the Uptake of Germline Genetic Testing in Non-Metastatic Breast Cancer and the Impact of Testing on Surgical Decision Making

  2023cites this paper